EGFR and non-small cell lung carcinoma: As a result of these studies, it became clear that there is a high degree of molecular heterogeneity in EGFR nonmutated NSCLC.80 Beyond NSCLC harboring EGFR‐ or other common mutations which can be targeted by biologicals, there is a certain gray zone of tumors as well (about 40% of NSCLC) which are negative for all molecular alterations that can be targeted by clinically approved drugs.